Lv1
20 积分 2024-07-15 加入
CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence
2天前
已完结
Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
4天前
已完结
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
4天前
已完结
Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
5天前
已完结
Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib
7天前
已完结
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
7天前
已完结
Ruxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndrome
7天前
已完结
Combination ruxolitinib, belumosudil, and axatilimab yields clinically significant symptomatic improvements in treatment-refractory chronic GVHD
12天前
已完结
Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma
16天前
已完结
Bispecific Antibodies for the Treatment of Multiple Myeloma
18天前
已完结
皖公网安备34019202002308
